Fortress Biotech, Inc. Amortization of Intangible Assets
Fortress Biotech, Inc. (FBIO) reported Amortization of Intangible Assets of $969.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-13
- Fortress Biotech, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $969.00K, a 8.93% decline year-over-year.
- Fortress Biotech, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $1.13M, a 5.73% increase year-over-year.
- Fortress Biotech, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $1.06M, a 8.56% increase year-over-year.
- Fortress Biotech, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $1.06M, a 30.71% increase year-over-year.
- Fortress Biotech, Inc. amortization of intangible assets for fiscal 2025 was $4.26M, a 24.36% increase from fiscal 2024.
- Fortress Biotech, Inc. amortization of intangible assets for fiscal 2024 was $3.42M, a 9.11% decline from fiscal 2023.
- Fortress Biotech, Inc. amortization of intangible assets for fiscal 2023 was $3.77M, a 11.92% decline from fiscal 2022.
- Fortress Biotech, Inc. amortization of intangible assets for fiscal 2022 was $4.28M.
| Period end | Amortization of Intangible Assets 1 month | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 4 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $969.00K 10-Q · filed 2026-08-13 | $2.10M 10-Q · filed 2026-08-13 | $3.16M derived: sum of 3 quarters · filed 2026-08-13 | $4.22M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.13M 10-Q · filed 2026-05-14 | $2.19M derived: sum of 2 quarters · filed 2026-05-14 | $3.25M derived: sum of 3 quarters · filed 2026-05-14 | $4.32M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.13M derived: sum of 2 quarters · filed 2026-03-31 | $3.19M derived: sum of 3 quarters · filed 2026-08-13 | $4.26M 10-K · filed 2026-03-31 | ||
| 2025-09-30 | $1.06M 10-Q · filed 2025-11-14 | $2.13M derived: sum of 2 quarters · filed 2026-08-13 | $3.19M 10-Q · filed 2025-11-14 | $4.17M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $1.06M 10-Q · filed 2026-08-13 | $2.13M 10-Q · filed 2026-08-13 | $3.11M derived: sum of 3 quarters · filed 2026-08-13 | $3.92M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-14 | $2.05M derived: sum of 2 quarters · filed 2026-05-14 | $2.86M derived: sum of 3 quarters · filed 2026-05-14 | $3.67M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $981.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.79M derived: sum of 2 quarters · filed 2026-03-31 | $2.61M derived: sum of 3 quarters · filed 2026-03-31 | $3.42M 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $814.00K 10-Q · filed 2025-11-14 | $1.63M derived: sum of 2 quarters · filed 2025-11-14 | $2.44M 10-Q · filed 2025-11-14 | $3.26M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $814.00K 10-Q · filed 2025-08-14 | $1.63M 10-Q · filed 2025-08-14 | $2.44M derived: sum of 3 quarters · filed 2025-08-14 | $3.26M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $814.00K 10-Q · filed 2025-05-15 | $1.63M derived: sum of 2 quarters · filed 2025-05-15 | $2.44M derived: sum of 3 quarters · filed 2025-05-15 | $3.51M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.63M derived: sum of 2 quarters · filed 2025-03-31 | $2.70M derived: sum of 3 quarters · filed 2025-03-31 | $3.77M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.88M derived: sum of 2 quarters · filed 2024-11-14 | $2.95M 10-Q · filed 2024-11-14 | $4.18M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.14M 10-Q · filed 2024-08-13 | $3.37M derived: sum of 3 quarters · filed 2024-08-13 | $4.38M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $1.07M 10-Q · filed 2024-05-15 | $2.30M derived: sum of 2 quarters · filed 2024-05-15 | $3.31M derived: sum of 3 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.24M derived: sum of 2 quarters · filed 2024-03-28 | $4.28M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.05M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $2.03M 10-Q · filed 2023-08-14 | |||||
| 2020-12-31 | $1.42M 10-K/A · filed 2021-04-09 | |||||
| 2019-12-31 | $1.17M 10-K/A · filed 2021-04-09 | |||||
| 2018-09-30 | $712.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.41M derived: sum of 2 quarters · filed 2018-11-09 | $2.10M 10-Q · filed 2018-11-09 | $2.52M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2018-06-30 | $698.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.39M 10-Q · filed 2018-08-09 | $1.80M derived: sum of 3 quarters · filed 2018-08-09 | $2.22M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2018-03-31 | $690.00K 10-Q · filed 2018-05-10 | $1.11M derived: sum of 2 quarters · filed 2018-05-10 | $1.52M derived: sum of 3 quarters · filed 2018-11-09 | $1.93M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2017-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $832.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.24M derived: sum of 3 quarters · filed 2018-11-09 | $1.65M 10-K · filed 2018-03-16 | ||
| 2017-09-30 | $416.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $827.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.24M 10-Q · filed 2018-11-09 | $1.24M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2017-06-30 | $411.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $819.00K 10-Q · filed 2018-08-09 | $819.00K derived: sum of 3 quarters · filed 2018-08-09 | $819.00K derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $408.00K 10-Q · filed 2018-05-10 | $408.00K derived: sum of 2 quarters · filed 2018-05-10 | $408.00K derived: sum of 3 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $509.00K 10-K · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $0.00 10-K · filed 2018-03-16 | ||
| 2016-09-30 | -$509.00K 10-K · filed 2017-03-16 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $0.00 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | |||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |